Log in

NEPH NEPHROS INC NASDAQ · United States

NEPHROS INC (NEPH) news

NEPHROS INC is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NEPH, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest NEPHROS INC news

We have not published a story on NEPHROS INC yet. When there is news, it will appear here.

NEPHROS INC annual financials

LineFY2025FY2024
Revenue$18.8 million$14.2 million
Research and development$1.3 million$906,000
Net income (loss)$1.2 million$74,000
Cash from operations$1.6 million-$492,000
Cash and equivalents$5.4 million$3.8 million

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $4.7 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about NEPHROS INC

What is the ticker symbol of NEPHROS INC?

NEPHROS INC trades under the ticker NEPH on NASDAQ.

Where is NEPHROS INC listed?

NEPHROS INC is listed on NASDAQ.

Which country or territory is NEPHROS INC listed under?

Our directory records NEPHROS INC under United States.

Does aibio.space cover NEPHROS INC?

aibio.space lists NEPHROS INC among 2,820 public biotech companies and publishes its news here as stories appear.

What was NEPHROS INC's revenue last year?

$18.8 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.

Is NEPHROS INC profitable?

NEPHROS INC reported net income of $1.2 million for the fiscal year ended Dec 31, 2025, and generated $1.6 million of cash from operations, per its annual report to the SEC.

How much does NEPHROS INC spend on research and development?

$1.3 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does NEPHROS INC have?

$4.7 million in cash at Jun 30, 2026, per its 10-Q.

Investor discussion: NEPHROS INC

Members talk about NEPHROS INC (NEPH). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:NEPH on TradingView.

Listing details

NEPHROS INC is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NEPH, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
NEPHROS INC
Ticker
NEPH
Listing
NASDAQ
Country or territory
United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.